Viatris/$VTRS

13:30
21:10
04:45
12:25
20:00
1D1W1MYTD1Y5YMAX

About Viatris

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.

Ticker

$VTRS
Primary listing

Industry

Pharmaceuticals

Employees

32,000

Viatris Metrics

BasicAdvanced
$11B
-
-$3.18
0.89
$0.48
5.13%

What the Analysts think about Viatris

Analyst ratings (Buy, Hold, Sell) for Viatris stock.

Bulls say / Bears say

Viatris has initiated a strategic review to streamline costs and position the organization for future growth, indicating proactive management aimed at enhancing operational efficiency. (GuruFocus)
The company has returned approximately $450 million to shareholders, including $300 million through share repurchases, demonstrating a commitment to shareholder value. (GuruFocus)
Viatris reported positive data for Phase 3 studies of novel fast-acting meloxicam for moderate to severe acute pain, highlighting its potential as a non-opioid treatment option. (GuruFocus)
Viatris faces a class action lawsuit alleging that the company misled investors regarding a failed inspection at its Indore, India facility, potentially leading to financial liabilities. (GuruFocus)
The company reported a non-cash goodwill impairment charge of $2.9 billion due to a decline in share price and increased business risk, reflecting potential challenges in asset valuation. (GuruFocus)
Viatris' North American business decreased 8% compared to the prior year, impacted by the Indore facility issues and competition on select generic products, indicating market challenges. (GuruFocus)
Data summarised monthly by Lightyear AI. Last updated on 12 Jul 2025.

Viatris Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Viatris Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $VTRS

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs